Approval · Notice of Compliance 17256 · 2015
ACT DUTASTERIDE: Notice of Compliance 17256
Issued September 4, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17256
- Date
- September 4, 2015
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in specifications
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT DUTASTERIDE | Not yet assigned | — |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP